Hemp Acquisition Reminds Investors to Focus on Hemp Plays

HENDERSON, NV / ACCESSWIRE / October 16, 2018 / Monday investors were reminded that hemp companies are a big part of the cannabis craze when Canopy Growth Corp. announced a deal to buy Ebbu Inc., a Colorado-based hemp researcher, in a stock-and-cash deal worth more than $425 million.

Under the agreement, Canopy will pay $25 million in cash and issue 6,221,210 shares to Ebbu.

This news had us on the lookout for other hemp players that could be potential candidates for acquisition. Chineseinvestors.com Inc. (CIIX) is our favorite of the lot. The company owns a hemp-infused, rice wine brand called CBD Hemp Wine through its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd. The fact that it is a CBD beverage only adds to the desirability as major consumer beverage brands, like Molson Coors and Coca Cola have been doing some shopping of their own.

CIIX is an interesting investment in acquisition or not the company had a 41% increase in revenue for fiscal 2018 over 2017 buoyed by a 28,859% increase in consumer product sales largely attributed to their CBD lines.

This was among the reasons SeeThru Equity decided to give the company a $3.75 price target.

This Thursday CIIX is presenting at a Virtual Investor Conference and will certainly draw a lot of interest. This may be a last chance to invest in CIIX before it goes parabolic at its current price it looks like a serious bargain.

CBD stocks to watch include: ChineseInvestors.com, Inc. (CIIX), Canopy Growth Corporation (CGC), Aurora Cannabis, Inc. (ACBFF), Aphria, Inc. (APHQF), and CV Sciences, Inc. (CVSI).

ChineseInvestors.com, Inc. (CIIX)

Market Cap: $27.94M Share Price: $0.78

ChineseInvestors.com (CIIX), announced that Chief Executive Officer Warren Wang will present live at VirtualInvestorConferences.com on October 18, 2018.

This will be a live, interactive online event where investors are invited to ask the company questions in real time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Canopy Growth Corporation (NYSE: CGC)

Market Cap: $12.19B Share Price: $53.10

Canadian pot company Canopy Growth Corp. said Monday it has agreed to acquire the assets of Colorado-based Ebbu Inc., a hemp research company, for CAD25 million plus 6.2 million shares.

Aurora Cannabis, Inc. (OTCQX: ACBFF)

Market Cap: $10.79B Share Price: $11.23

The company released fiscal fourth-quarter earnings and confirmed its intention to list stock on a “senior” U.S. exchange such as the Nasdaq or the New York Stock Exchange.

Further to this on Friday, October 5, the company filed a Form-40 with the intent of registering its securities on the New York Stock Exchange. Aurora could join the ranks of a growing number of cannabis companies choosing to list on major exchanges in the US. Late last month, Canaccord Genuity raised its price target for Aurora Cannabis to 13 Canadian dollars from 11 Canadian dollars.

Aurora Chief Executive Terry Booth said, “This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success.”

Aphria, Inc. (APHQF)

Market Cap: $3.26B Share Price: $14.13

Aphria Inc. (APHQF) announced closing the acquisition of LATAM Holdings Inc. from Scythian Biosciences (SCCYF). The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018.

CV Sciences, Inc. (OTCQB: CVSI)

Market Cap: $542.47M Share Price: $5.60

CV Sciences (CVSI) has received more positive attention after it announced that it had appointed Joseph Maroon, MD, FACS to its Board of Directors. The Nevada-based company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. CIIX

has paid forty-nine thousand dollars and twenty thousand restricted shares for corporate awareness services for the month of October, and continues to pay Regal to disseminate truthful and potentially material information regarding CIIX.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in CIIX can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX. CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of CIIX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC